Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

06/21/2013 | 05:03am US/Eastern

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
Latest news
Date Title
1m ago SUPER MICRO COMPUTER : beats Street 1Q forecasts
2m ago GLOWPOINT : to Announce Third Quarter Results on November 5, 2014
2m agoDJHungary Plans to Tax Internet Use with Levy on Service Providers
3m ago NEXCOM : Breaks Ground For Headquarters Building Expansion
3m ago KYTHERA BIOPHARMACEUTICALS : Grants Stock Options Under Inducement Program
3m agoDJDaimler Sells 4% Stake in Tesla Motors
3m ago RAIT FINANCIAL : Schedules Third Quarter 2014 Financial Results Release Date and Conference Call
3m ago RAIT FINANCIAL : Independence Realty Trust Schedules Third Quarter 2014 Financial Results Release Date and Conference Call
3m ago BILL GROSS : Ford Motor says will drop Pimco Total Return Fund from its 401k plan
4m ago TESLA MOTORS : Daimler sells stake in Tesla for $780 million
Latest news
Advertisement
Hot News 
DOMINION MIDSTREAM PARTNERS : Closes Initial Public Offering
TUESDAY SECTOR LAGGARDS : Metals & Mining, Education & Training Services
STRATMIN GLOBAL RESOURCES : Seals Offtake Agreement With Independent Global Graphite Merchant
BLUE EARTH : INVESTOR ALERT: Investigation of Blue Earth, Inc. Announced by Glancy Binkow & Goldberg LLP
OCWEN FINANCIAL : Addresses Letter From New York Department of Financial Services
Most Read News
55m ago Wall St. extends rebound on earnings, ECB report
8h ago Total CEO de Margerie killed in Moscow as jet hits snow plough
33m ago Global shares rally on U.S. tech earnings, ECB purchase plans
1d ago GULFMARK OFFSHORE : Announces Third Quarter 2014 Operating Results
1d ago Chipotle stock dips as sales growth forecasts come down
Most recommended articles
2m agoDJHungary Plans to Tax Internet Use with Levy on Service Providers
3m agoDJDaimler Sells 4% Stake in Tesla Motors
3m ago BILL GROSS : Ford Motor says will drop Pimco Total Return Fund from its 401k plan
9m agoDJOil Prices Edge Higher on Chinese Data
10m agoDJCOCA COLA : Correction to Coke Promises Cost Cuts Story
Dynamic quotes  
ON
| OFF